Prolactinoma historical perspective: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 18: | Line 18: | ||
[[Category:Neuroendocrinology]] | [[Category:Neuroendocrinology]] | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[ | [[Category:Oncology]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Primary care]] | [[Category:Primary care]] |
Revision as of 19:24, 16 October 2017
Prolactinoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Prolactinoma historical perspective On the Web |
American Roentgen Ray Society Images of Prolactinoma historical perspective |
Risk calculators and risk factors for Prolactinoma historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2], Faizan Sheraz, M.D. [3]
Overview
In 1970, prolactin was discovered in humans by a sensitive bioassay (Nb2 cell bioassay). In 1978, V C Medvei, the President of the Section of History of Medicine (1986-87) of the Royal Society of Medicine in London, wrote in his paper that Queen Mary I of England was believed to have prolactinoma.
Historical Perspective
Famous Cases
- In 1978, V C Medvei, the President of the Section of History of Medicine (1986-87) of the Royal Society of Medicine in London, wrote in his paper that Queen Mary I of England was believed to have prolactinoma.[2]
References